Open Nav

Second Genome, Inc.

  • Karim Dabbagh, Second Genome, Inc.

Introduce company/assets and gain interest for Series C funding

  • Date:Wednesday, October 17
  • Time:2:45 PM - 3:00 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Second Genome is a clinical stage company focused on discovering and developing therapeutics derived from the microbiome. This is done by utilizing our robust drug discovery platform, which elucidates and interrogates important microbial products that strongly influence human health and disease. These products are empirically tested through standard drug discovery processes, such as cell-based assays and in vivo models, to identify those that positively or negatively influence a particular disease. Second Genome's pipeline includes a P2X7 modulator entering Phase 2 for NASH in 2018, and a preclinical asset entering Phase 1 for mucosal healing in 2019. The company also has exciting, novel data in our immuno-oncology program, further validating the microbiome impact on response to immunotherapy. Our strategy is to move quickly into the clinic using our proprietary platform, partner certain internal assets and offer broad use of our platform for partner's areas of interest.
  • Company
  • Company HQ City:South San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Karim Dabbagh
  • Year Founded:2010
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development :SGM-1019
  • Development Phase of Primary Product:Phase II
  • Previous and Current Investors:Morgenthaler, ATV, Roche Venture Fund, SR One, Pfizer Venture Fund
  • Size of Last Investment Round:$51M
  • Total Amount Raised to Date, In All Rounds:$67M
Karim Dabbagh
Second Genome, Inc.